(Total Views: 496)
Posted On: 06/26/2021 3:06:32 PM
Post# of 72447
Unbinding is performed following the collection of ALL data. UNLESS, with a nod from the FDA an acceleration of project timeline is approved. An acceleration that would, as an example, permit unbinding following collection of +29 data.
Without FDA approval the protocol will not change.
FDA approval of acceleration is extremely, extremely unlikely. (Did I mention extremely unlikely?)
Top line results, at earliest, August. More likely top line results in early September. (Data unbinding, mapping and interpretation must be done in a cautious and methodical fashion)
But July’s American Society for Virology conference and August’s Military Health System Research Symposium combined with anticipation of results should generate excitement and hopefully an uptrend for the stock.
Without FDA approval the protocol will not change.
FDA approval of acceleration is extremely, extremely unlikely. (Did I mention extremely unlikely?)
Top line results, at earliest, August. More likely top line results in early September. (Data unbinding, mapping and interpretation must be done in a cautious and methodical fashion)
But July’s American Society for Virology conference and August’s Military Health System Research Symposium combined with anticipation of results should generate excitement and hopefully an uptrend for the stock.
(1)
(0)
